Next Article in Journal
Validation of a Machine Learning Model to Predict Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
Next Article in Special Issue
Urine-Based Biomarker Test Uromonitor® in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer—A Systematic Review and Meta-Analysis of Diagnostic Test Performance
Previous Article in Journal
Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [68Ga]Ga-RM2—A Head-to-Head Pilot Comparison with [68Ga]Ga-PSMA-11
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 1
10.3390/cancers16010174
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Low Alanine Aminotransferase as a Marker for Sarcopenia and Frailty, Is Associated with Decreased Survival of Bladder Cancer Patients and Survivors—A Retrospective Data Analysis of 3075 Patients

Cancers 2024, 16(1), 174; https://doi.org/10.3390/cancers16010174
by Menachem Laufer 1,2,†, Maxim Perelman 2,3,†, Gad Segal 2,4,*, Michal Sarfaty 2,5 and Edward Itelman 2,6,7
Reviewer 1: Anonymous
Reviewer 2:
Simone Cilio
Cancers 2024, 16(1), 174; https://doi.org/10.3390/cancers16010174
Submission received: 25 November 2023 / Revised: 23 December 2023 / Accepted: 26 December 2023 / Published: 29 December 2023
(This article belongs to the Special Issue New Insights into Urologic Oncology)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

It is my pleasure to review this paper entitled “Low Alanine Aminotransferase as a Marker for Sarcopenia and Frailty, is Associated with Decreased Survival of Bladder Cancer Patients and Survivors. A Retrospective Data Analysis of 3075 Patients”. The aim of this paper is to evaluate the possible association between low serum ALT, and shorter survival bladder cancer patients and to offer a new tool for urologists and oncologists, for treating these patients. However, there are some drawbacks that could be addressed before an eventual publication.

Introduction should be revised it is too much long.

Authors should highlight the strengths and limitations of the paper.

Line 200 please clarify the meaning of L3SMI.

Author Response

Attached please find a point-by-point answers to review.

On behalf off all authors I thank you very much.

Gad Segal, MD. 

Author Response File: Author Response.docx

Reviewer 2 Report

Comments and Suggestions for Authors

I would congratulate the authors for their work and for addressing an important topic. Only some points warrant mention:

 

1.    In the “Introduction” section, I suggest to improving this section regarding recent research on serum markers useful in the early detection and diagnosis of bladder cancer

2.    In the “Results” section, “Figure 2” should be improved by adding the numerosity of the population at risk, otherwise it cannot be defined as a Kaplan-Meier curve.

3.    In the “Discussion” section, when discussing on alteration of BMI, the authors should also include a brief mention of the opposite case, such as obesity, and its associated alteration of triglycerides and cholesterol and BCa, such as in PMID: 35204522.

4.    In the “Discussion” section, the term “and co.” should be replaced with “et al.”

Author Response

Attached please find a point-by-point answers to review.

On behalf off all authors I thank you very much.

Gad Segal, MD. 

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

Comments and Suggestions for Authors

I want to thanks the authors for the changes

Author Response

We thank you very much

Back to TopTop